Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies
Autor(es): Feasby T E
Resumo: Three patients with acute Guillain-Barré syndrome were treated early in the course of the disease with OKT3, an anti-T-cell monoclonal antibody. Each patient developed acute lymphopenia with specific depletion of T3-positive lymphocytes. Two patients had continued progression of clinical deficits for eight and 14 days. This suggests that T lymphocytes may not be essential for progression of Guillain-Barré syndrome at this stage of the disease.
Imprenta: Journal of Neurology, Neurosurgery, and Psychiatry, v. 54, n. 1, p. 51-54, 1991
Identificador do objeto digital: 10.1136/jnnp.54.1.51
Descritores: Guillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Clinical examination ; Guillain-Barre Syndrome - Immunology ; Guillain-Barre Syndrome - Public health
Data de publicação: 1991
